ALLR vs. ADTX, BLPH, AMPE, APVO, SXTC, ATHX, CALA, EVFM, EVLO, and SPRC
Should you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Aditxt (ADTX), Bellerophon Therapeutics (BLPH), Ampio Pharmaceuticals (AMPE), Aptevo Therapeutics (APVO), China SXT Pharmaceuticals (SXTC), Athersys (ATHX), Calithera Biosciences (CALA), Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.
Aditxt (NASDAQ:ADTX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
Allarity Therapeutics has a net margin of 0.00% compared to Allarity Therapeutics' net margin of -5,016.31%. Aditxt's return on equity of 0.00% beat Allarity Therapeutics' return on equity.
Aditxt received 3 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. However, 50.00% of users gave Allarity Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Aditxt has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
In the previous week, Allarity Therapeutics had 2 more articles in the media than Aditxt. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Aditxt. Allarity Therapeutics' average media sentiment score of 1.38 beat Aditxt's score of -0.10 indicating that Aditxt is being referred to more favorably in the media.
Aditxt currently has a consensus price target of $61.00, indicating a potential upside of 2,647.75%. Given Allarity Therapeutics' higher possible upside, research analysts clearly believe Aditxt is more favorable than Allarity Therapeutics.
Allarity Therapeutics has lower revenue, but higher earnings than Aditxt.
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 1.2% of Aditxt shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Aditxt beats Allarity Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Allarity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allarity Therapeutics Competitors List
Related Companies and Tools
